CRDF News and Press, Cardiff Oncology Inc. From 11/21/22

Cardiff Oncology to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

Cardiff Oncology to Present at the Jefferies London Healthcare Conference PR Newswire SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therap...

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and research is constantly advancing. Pancreatic cancer is 12 ...

Cardiff Oncology press release ( NASDAQ: CRDF ): Q3 GAAP EPS of -$0.20 beats by $0.06 . Revenue of $0.09M (+12.5% Y/Y) beats by $0.02M . Shares +0.7% . Cash, cash equivalents, and short-term investments of approximately $114 million as of September 30, ...

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates PR Newswire Data from Phase 1b /2 trial in KRAS-mutated metastatic colorectal cancer (mCRC), per September 12 th announcement, show durable responses to treatment and support ...

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide markets. The COVID-19 pandemic has impacted the who...

Summary In a tremendous overreaction, Cardiff lost 41% of its value over the discontinuation of a prostate cancer trial on September 13, 2022,. Combined ESMO 2022 oncology conference reportings by Amgen, Mirati Therapeutics and Cardiff show Onvansertib is best-in-class in metastat...

The shares of clinical-stage biotech Cardiff Oncology ( NASDAQ: CRDF ) shed ~19% in pre-market trading Tuesday after the company announced plans not to allocate further funding for its clinical studies in metastatic castrate-resistant prostate cancer (mCRPC). The decisio...

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates PR Newswire Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 tri...

Clinical-stage biotech Cardiff Oncology ( NASDAQ: CRDF ) added ~14% in the pre-market trading Monday after the company announced Phase 1b/2 data for its lead asset Onvansertib in patients with KRAS-mutated metastatic colorectal cancer in a second-line setup. The data fea...